Lupus & antiphospholipid syndrome
Antiphospholipid antibodies as potential predictors of disease severity and poor prognosis in systemic lupus erythematosus-associated thrombocytopenia: results from a real-world CSTAR cohort study
Authors' conclusion
SLE-TP patients with positive aPLs had more severe disease a lower remission rate but a higher relapse rate.
Study context
- Population
- Patients with SLE-related thrombocytopenia (platelet count<100 × 109/L) with complete follow-up data, CSTAR registrycomplete follow-up data
- Participants
- 350 patients
- Exposure
- aPL-positive vs aPL-negative SLE-TP
- Outcome
- Baseline platelet count
- Follow-up
- Baseline
Methodological detailsmulticentre, registry-based (CSTAR)
- Multicentre
- Registry-based (CSTAR)
Main finding
As reported in the abstract
P < 0.001
Observational data: associations, not effects.
Further findings
Lowest platelet count
P = 0.002
Relapse rate · follow-up
P = 0.009
- Moderate to severe cases · baseline
- P < 0.001
Moderate to severe cases · baseline
- Higher proportion of moderate to severe cases with aPLs (24.2% vs. 14.1% ; 18.0% vs. 8.3%)
Number of aPL types and baseline and minimum platelet values
- Increasing number of aPLs types associated with decrease in baseline and minimum platelet values (P<0.001, P = 0.001)
Complete response rate · follow-up
- Lower complete response (CR) rate with aPLs
- As aPL types increased, relapse rate increased and CR rate decreased
Bone marrow findings
- No significant difference in G/E ratio, total number of megakaryocyte and categories
Parts of this Brief are withheld: the automatic checks could not confirm them against the abstract.
Original publication
Antiphospholipid antibodies as potential predictors of disease severity and poor prognosis in systemic lupus erythematosus-associated thrombocytopenia: results from a real-world CSTAR cohort study. Arthritis Res Ther. Published 12 March 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →